Finding the best therapeutic options in the world

Finding the most relevant therapeutic options available worldwide has become a structural challenge. Medical innovation now advances at a pace that exceeds the capacity of health systems to disseminate it. An option validated in one country may be unknown in another. A protocol may be in use in a single institution without ever having been published. A technique may be practised by one team without any of its immediate peers being aware of it.

The barriers to this dissemination are numerous, deep and often invisible: editorial, commercial, regulatory, institutional, human, competitive, linguistic. They are not a sign of a failure of the health system. They are the mechanical consequence of a world in which the production of medical knowledge structurally outpaces the infrastructure designed to spread it.

This is precisely what Bytlian's Independent Global Therapeutic Exploration is designed to cross: these barriers, one by one, with a methodology built over ten years to identify and circumvent them. To learn more: bytlian.com

This document does not constitute a medical act. Every therapeutic decision is the exclusive responsibility of physicians.

Medical innovation is globalising at high speed. An approach may be approved in one jurisdiction before another. A technique may be practised in a single centre worldwide. A protocol may be validated in a multidisciplinary case conference without yet being the subject of an indexed publication.

To know whether an option exists elsewhere, one must consult the regulatory approval registries of every major jurisdiction, the international scientific literature, specialised medical congresses, and conduct direct enquiries with the research teams concerned. These steps are not accessible through a standard internet search or an LLM prompt.

The Independent Global Therapeutic Exploration covers the entire world and dozens of databases to answer this question precisely. The geography of medical innovation does not match the geography of care.

Yes. Bytlian is a global independent therapeutic intelligence service whose mission is precisely to explore the worldwide therapeutic landscape for a given clinical profile.

This undertaking is more complex than its description suggests. It requires accessing sources, many of which are not public, crossing linguistic, regulatory, institutional and human barriers, mobilising direct investigation with experts who do not publish everything they know, and submitting the whole to the validation of an independent scientific committee constituted for each case.

The deliverable is a structured document handed to the treating medical team. It does not constitute a medical act and does not replace any clinical decision. Its purpose is to widen the map available at the moment of decision.

Medical innovation is not limited to new molecules. It takes many forms: surgical techniques developed in a single centre, combined protocols validated in practice before being published, medical devices from small structures with no sales force, rehabilitation or non-pharmacological care approaches, or new indications for options already approved for other situations.

A large share of these innovations cannot be found in standard information sources. Some are published behind paywalls in low-circulation journals. Others are known only to the teams that practise them. Still others are approved in one jurisdiction and intentionally not developed in another for commercial reasons.

Accessing these innovations in a structured way requires dedicated sourcing infrastructure, a direct-investigation methodology, and human validation of the results. This is the architecture Bytlian has built over ten years of global therapeutic scouting.

It is rarely possible to answer this question from within a single institution or a single health system. Medical practices vary across countries, clinical traditions, the pace of regulatory adoption, and the speed at which recommendations spread.

The average delay between a significant scientific discovery and its adoption in clinical practice is estimated at 17 years. The barriers to the dissemination and adoption of medical innovation are numerous and structural: a publication may be lost among thousands of others, published in a little-read language, or in a specialty that the relevant practitioners do not read. An innovation may be developed by a structure with no commercial network, approved in one jurisdiction but never launched in another. A protocol may be blocked by institutional rivalries or held back while awaiting publication priority. A specialist may hold tacit knowledge that was never formalised, which will disappear when they retire.

Verifying whether care matches the global state of the art means crossing these barriers, one by one. This is one of the missions of the Independent Global Therapeutic Exploration.

This service does not call into question physicians' clinical judgement. It ensures they have the most complete map possible at the moment of decision.

Identifying the most advanced medical teams on a precise subject is one of the most difficult exercises in global therapeutic exploration. And one of the tasks at which intuitive approaches most often fail.

Scientific publication is a useful indicator, but an insufficient one. A team that publishes a great deal is not necessarily at the cutting edge of clinical practice. A leading-edge team does not necessarily publish: for lack of time, as an intellectual-protection strategy, out of academic rivalry, or simply because its results are recent and have not yet completed the editorial process. Some of the most advanced teams we have identified had not published for several years.

General hospital rankings say nothing about a team's competence for a specific situation. An institution may be world-renowned in many fields and not be the right contact for a particular situation.

Identification requires cross-referencing heterogeneous signals: recent publications, yes, but also the direction of research programmes, participation in international networks, reputation at specialised congresses, and above all direct investigation with other specialists in the field. What peers know about one another appears in no database.

Bytlian carries out this work as part of every exploration. It is one of the most time-consuming and least mechanisable parts of the process.

Not all innovations are relevant to all clinical profiles. An approach may produce remarkable results in a precise population and be of no interest, or even harmful, in another. The assessment of clinical relevance rests on the comparison between the patient's characteristics and those of the populations studied in the available data.

This analysis requires understanding the innovation's mechanism of action, its documented indications, its efficacy and tolerability profile, its level of clinical development, and the eligibility criteria defined. It also requires access to complete data, including data not yet published or found in study subgroups that are rarely highlighted.

Bytlian's independent scientific committee assumes this qualification function for each case. It does not merely identify innovations: it assesses their real clinical relevance in the patient's specific context, with the rigour of an expert medical reading.

Finding the most relevant specialists for a precise medical situation is a process that resists all automation. It is one of the most complex tasks in global therapeutic exploration.

The most advanced specialists on a given problem are not always visible. Some publish little. Others have a practice recognised only within their immediate network. Still others have developed expertise on a very precise sub-population, which does not surface in a standard keyword search. And some, paradoxically, are known to all their peers without ever having published the core of their know-how.

Documentary analysis alone, however rigorous, is insufficient. Identifying the most relevant specialists almost always involves direct investigation: questioning peers, mobilising networks, cross-referencing signals that only human enquiry can assemble.

Bytlian conducts this identification as part of its explorations. The aim is not to find the most publicised specialist, nor the most cited, but the one whose expertise genuinely matches the clinical situation under study.

Medical practices vary appreciably from one country to another. These differences reflect clinical traditions, distinct regulatory frameworks, different rates of adoption of innovations, and sometimes unequal levels of research investment.

Comparing these approaches involves examining the professional recommendations of each major jurisdiction, the published care strategies, and the practices of expert centres in each region. But that is not enough: actual practices often diverge from official recommendations, and some of the most advanced approaches are documented nowhere.

This is one of the structural contributions of the Global Therapeutic Exploration: its geographic scope is explicitly worldwide, because medical innovation is distributed worldwide, and because its dissemination barriers are also worldwide.

Many relevant therapeutic options remain low in visibility not because they are experimental or unvalidated, but for reasons that have nothing to do with their clinical value: a company with no commercial network, a protocol that never left the walls of an institution, a publication in a little-read journal, a specialist who does not publish, a regulatory approval obtained but commercially abandoned in certain countries, or rivalries between teams that delay the dissemination of a result.

Identifying them requires mobilising a process of direct enquiry with specialists, researchers, hospital teams and other actors in the medical ecosystem, in addition to accessing private and institutional documentary sources.

It is this combination, human investigation and access to data unreachable by standard routes, that enables Bytlian to identify what neither an internet search nor a general-purpose AI model can find: information that exists but has not yet circulated, and sometimes is not meant to circulate.

New therapeutic approaches rarely appear simultaneously in every country, with the exception of innovations benefiting from sufficient commercial resources for a coordinated global rollout. An innovation may be developed in a university, adopted by a few pioneering teams, and take years before being widely disseminated, if it ever is.

To know whether a new approach exists somewhere, one must explore heterogeneous sources, cross-reference disparate signals, and conduct direct enquiries with the teams most active in the field. A search limited to indexed publications will systematically miss what is emerging.

The boundary between an emerging innovation and a mature option must be carefully qualified. This is the role of the independent scientific committee in Bytlian's architecture: to validate, prioritise, and qualify the level of evidence of each option identified.

The question implicitly assumes that the latest medical advances are published somewhere and accessible. That assumption is partly false, and this is precisely where the problem lies.

A significant share of the most recent and most relevant advances is not published, not yet published, or published under conditions that make it practically impossible to find: behind a paywall, in a low-circulation journal, in a little-read language, in a specialty that the relevant practitioners do not consult, or in conference proceedings that were never indexed.

Other advances exist in a form that gives rise to no publication at all: a locally developed protocol, a technique passed from practitioner to practitioner, a result held back awaiting publication priority, or tacit knowledge held by a team that has neither the time nor the interest to formalise it.

The Independent Global Therapeutic Exploration is designed precisely to access these sources, unreachable by standard routes, by combining an extensive documentary infrastructure with direct investigation among the actors who know what publications do not yet say.

Exploring every option available for a medical situation requires a methodical and multidimensional approach. Conventional approaches often represent only a fraction of what actually exists.

Therapeutic innovation takes many forms beyond new molecules: surgical or interventional techniques, medical devices, rehabilitation or non-pharmacological care protocols, combined strategies, new indications for options already approved. A complete exploration covers all these dimensions.

The aim is not to accumulate as much information as possible, but to obtain a structured, qualified mapping of the possibilities genuinely relevant to a precise clinical profile. This is what Bytlian produces: a document designed for the treating medical team, validated by an independent scientific committee, with full attribution of sources.

The search for medical options on a global scale rests on a fundamental conviction: no institution, no country, no network holds, on its own, the entirety of the knowledge relevant to a given situation.

A global approach explores several dimensions simultaneously: approaches validated in different jurisdictions, practices emerging in unexpected geographies, innovations carried by actors with no international visibility, and tacit knowledge held by teams that do not publish.

Over ten years, Bytlian has built the methodology and expertise required for this exploration: several hundred missions of innovation scouting and evaluation of technologies and the structures behind them, conducted across the world, in partnership with CentraleSupélec / Université Paris-Saclay, ranked first worldwide in mathematics.

Personalised medical monitoring consists of tracking, in a targeted way, the evolution of knowledge concerning a particular clinical profile, in order to identify new options as they emerge.

Unlike general monitoring, the aim is to filter the entire body of global medical output to retain only what is likely to have an impact on a precise situation. This filtering is itself a complex task that cannot be delegated to an automated tool.

Bytlian offers this dimension within the Medical Family Office: a permanent membership that includes continuous monitoring, activation within the hour in the event of a medical situation, and priority access to the scientific committee. The maximum value of such a service is anticipatory, subscribed before any crisis.

A specialised centre is not defined by its size or general reputation. An institution may be excellent in many fields without holding real experience of a precise situation. And it is by definition impossible for any one centre, however prestigious, to be at the cutting edge of global innovation in every field.

Identification rests on several criteria: volume of patients treated for that precise situation, contribution to international recommendations, recognition within expert networks. But these formal criteria are not enough. Some advanced centres do not publish. Others belong to no official network yet concentrate an exceptional practice.

In certain medical situations, only a few centres concentrate a significant share of the world's expertise. They are hard to identify without an in-depth documentary analysis complemented by direct investigation within specialised networks. Bytlian carries out this work as part of every exploration.

This question is at the heart of the Therapeutic Intelligence Gap, Bytlian's founding concept. The Therapeutic Intelligence Gap denotes the gap between the therapeutic options that exist in the world and those that are actually visible to a patient and their medical team at the moment of decision.

Answering this question means comparing current care with what exists on a global scale: recent recommendations, the practices of expert centres, available therapeutic innovations, approaches validated in other jurisdictions.

The answer is not always that a better option exists. In some cases, the exploration confirms that the strategy already in place does indeed match the global state of the art. This confirmation has value in itself: it allows decisions to be made with confidence.

Therapeutic innovation takes many forms. Beyond new molecules, it includes medical devices, surgical or interventional techniques, combined protocols, non-pharmacological care approaches, new indications for options already approved, and rehabilitation or follow-up strategies developed in certain centres.

Innovation does not necessarily mean superiority, or even novelty. A little-known option may rest on a considerable level of evidence. A recent approach may have insufficient data. The qualification of the level of evidence is inseparable from identification.

For this reason, Bytlian structurally separates exploration, conducted with tools and thorough enquiry, from validation, conducted by the independent scientific committee. One identifies. The other qualifies.

International medical expertise is spread across tens of thousands of universities, hospitals, laboratories, medtechs, biotechs and research centres. No single entity concentrates it. And a large part of this expertise is not accessible through the usual documentary routes.

Identifying the right experts is one thing. Accessing them is another. Some specialists do not respond to outside requests. Others share their knowledge only with their direct peers. Still others hold knowledge that no one else in the world possesses, and that has never been put in writing.

Accessing this expertise is not merely about identifying active teams and studying their publications. It requires building an access strategy: through which channels, with which intermediaries, in what context, and with what legitimacy. This is a part of Bytlian's work that nothing automates.

For members, accessing this expertise does not necessarily mean travelling abroad. In the vast majority of cases, the information produced by the exploration can be passed to the treating medical team, which integrates it into its decision-making.

The fear of missing an important option is one of the most legitimate concerns in the face of a complex medical situation. It is also one of the hardest to resolve on one's own.

The Therapeutic Intelligence Gap is structural: the production of medical knowledge advances faster than its dissemination. What the treating team does not know, it does not know that it does not know. The absence is invisible.

Our Independent Global Therapeutic Exploration is designed to reduce this probability of omission. It does not guarantee that an additional option exists. It guarantees that if an option exists, it will be sought everywhere it might be found.

This document does not constitute a medical act. Every therapeutic decision is the exclusive responsibility of physicians.

When a treatment does not produce the expected results, the first step is to understand why: natural progression of the medical situation, biological resistance, an underlying clinical change, or simply an evolution requiring a reassessment of the strategy.

Once this is established, exploring the available alternatives becomes a priority. These alternatives can take many forms: other therapeutic lines, innovative approaches, options available in other countries, or participation in a research programme.

Bytlian's Independent Global Therapeutic Exploration responds precisely to this situation. It maps all the relevant options on a global scale, qualified by level of evidence, drawing on sources the treating team cannot monitor on its own.

After several attempts without the expected result, it is natural to feel that the options are exhausted. This feeling often reflects the natural limits of any one actor's visibility over the global medical ecosystem, not the reality of that ecosystem.

Medical knowledge evolves continuously. New approaches become accessible over time. New scientific data alter the assessment of existing options. What did not exist six months ago may exist today.

Bytlian was designed for this situation: to conduct a structured, independent exploration, with access to private and institutional sources, in order to verify methodically whether relevant options have not yet been identified.

Obtaining a broader view means placing a medical case within the context of all the knowledge available on a global scale. This makes it possible to better understand where the situation stands relative to the state of the art, and what options exist beyond the usual frame.

This process involves examining the most recent recommendations across all major jurisdictions, specialised expert centres, ongoing research, and therapeutic innovations likely to have an impact.

It may confirm that the strategies already explored do indeed match the best global practices. It may also reveal avenues not yet considered. In both cases, the decision is better informed.

Modern medicine evolves at a pace that makes it difficult, for any actor taken in isolation, to maintain exhaustive visibility over all relevant developments. For a single medical situation, several generations of approaches may coexist.

Determining whether other options exist requires consulting multiple sources: international recommendations, public and private scientific literature, and direct enquiries with research teams.

It is also important to distinguish the levels of options available: validated and available approaches, options under clinical evaluation, emerging protocols. This qualification is inseparable from identification.

When conventional options seem limited, the visibility available from within a single institution or a single health system is rarely sufficient to conclude that nothing else exists.

Innovative approaches may emerge in low-visibility specialised centres. Options validated in certain jurisdictions may not yet have spread to others. Protocols may exist, known to a few specialists, without yet being the subject of a widely circulated publication. Innovations may be approved but commercially absent in certain countries for purely strategic reasons. Thus, many European start-ups establish themselves first on the US market as soon as the necessary FDA authorisations are obtained, neglecting their own domestic markets.

The Independent Global Therapeutic Exploration methodically checks all these possibilities. Even when no additional option is identified, this verification has value in itself: it allows decisions to be made with the certainty that the global landscape has been explored.

New therapeutic avenues can come from very diverse sources: approaches recently validated in another geographic area, new indications for existing options, recent biological or medtech discoveries, practices developed in low-visibility specialised centres, or innovations carried by actors with no means of dissemination.

Effective identification requires cross-referencing the characteristics of the clinical profile with the most recent advances in the field concerned. Some avenues become visible only through a fine-grained analysis of little-circulated publications or direct enquiries within specialised networks.

Bytlian carries out this work as part of its explorations, systematically distinguishing promising avenues from still-speculative hypotheses. Identification and qualification are separate stages in the service's architecture.

The search for alternatives begins with a precise understanding of the current medical situation: options already used (or considered), results obtained, reasons justifying the exploration of new avenues. This basis is essential to direct the exploration effectively.

Alternatives can take many forms: other pharmacological approaches, combined strategies, innovative medical devices, options available in other health systems, or non-pharmacological approaches validated in certain centres.

An effective exploration is not about accumulating possibilities. It aims to select the most relevant options in light of the clinical profile and the level of evidence available. The distinction between exploration and qualification is one of the keys to our approach.

An in-depth exploration rests above all on the quality of the information available about the medical situation. The more precise the understanding of the clinical profile, the more it is possible to identify genuinely relevant options.

Preparation involves gathering the essential elements of the case: documented diagnosis, relevant biological or genetic tests, options already considered, results observed, and recent clinical evolution.

Once this basis is established, the exploration can extend to the entire global landscape. Bytlian can begin an exploration within the hour following receipt of a complete case file.

Extending the search internationally is relevant in many situations, not only the most serious cases. It can be useful from the moment of diagnosis to understand the global state of the art. It becomes particularly important when the options identified locally seem insufficient, or when there is strong innovation momentum in the field concerned.

Some approaches are the subject of very active development in certain regions of the world. Innovative protocols or specialised expertise may exist outside the usually accessible frame, in countries that nothing would, a priori, designate as centres of excellence for that situation.

There is no need to wait for a critical situation. Bytlian is designed as an anticipation service: the optimal value of a membership is preventive, subscribed before any medical crisis.

A complex medical situation can quickly create the feeling that events are slipping out of control. Adopting a methodical approach makes it possible to regain an active stance without substituting for healthcare professionals.

This approach may include a better understanding of the medical situation, the exploration of scientific knowledge available on a global scale, the identification of the teams most advanced on the problem, and verification that the available options have been systematically mapped.

We produce this mapping in a structured and independent way. The deliverable is handed to the treating medical team, which integrates it into its exchanges with the patient if it deems it relevant to do so. The aim is to enrich the clinical decision, not to replace it.

Verifying that all relevant avenues have been explored is structurally difficult from a single vantage point. An institution does not know what it does not know. A physician cannot point to an option of which they are unaware.

This verification requires an independent exploration, conducted from a vantage point distinct from the patient's usual health system, with access to sources that system does not consult.

This is one of the main functions of the Independent Global Therapeutic Exploration. Its result may be a confirmation that the avenues already explored are the right ones. It may also reveal options not yet considered. In both cases, the process produces value.

Little-known options exist in several categories. Some are carried by structures with no commercial sales force. Others are practised in a single centre worldwide. Still others are validated in one jurisdiction without yet having spread to the others. Others are known to specialists without yet having been formalised in a widely indexed publication. And some are deliberately kept from circulating, as a commercial strategy or out of academic rivalry.

Identifying them requires going beyond standard information sources: private databases, direct enquiries with researchers and hospital teams, monitoring of specialised congresses, and hard-to-reach expert networks.

This is precisely the field-investigation layer that Bytlian conducts in every exploration. Documentary research alone is not enough to find what has not yet circulated.

Second- or third-line options correspond to the strategies worth considering when an initial approach does not produce the expected results. They are often more numerous than imagined, and some of them are available only in certain jurisdictions.

Their exploration requires a precise understanding of the reasons that led to the change of strategy: biological resistance, adverse effects, clinical progression. These elements direct the search for alternatives differently.

An analysis of international recommendations and the practices of expert centres often makes it possible to identify options that do not yet feature in local practice. Bytlian carries out this analysis as part of its explorations, covering the entire world and all the major regulatory jurisdictions.

Situations resistant to standard approaches are often at the heart of the most intense medical research efforts. Universities, hospital centres, biotechnology companies and academic programmes continually develop new approaches to address unmet therapeutic needs.

To identify them, one must explore the recent scientific literature, expert centres, therapeutic innovations under development, and conduct direct enquiries with the most advanced actors. Some options are already available in clinical practice in certain countries. Others are still under evaluation.

Bytlian is particularly relevant in these situations. The systematic exploration of the global landscape, with access to private sources, the field-investigation work and validation by an independent scientific committee, is designed precisely to map what exists beyond the approaches already tried.

An apparent therapeutic dead end often results from the limited visibility available from within a single health system. It does not necessarily mean the absence of options.

The appropriate course is to conduct a structured, independent exploration of the entire global therapeutic landscape, accessing the sources the treating team cannot monitor on its own, and having the results validated by an independent scientific committee.

Even when such an exploration confirms that no additional option is available at the time it is conducted, this conclusion has value in itself. It allows future decisions to be made with the certainty that the global landscape has been examined. Bytlian refers to this outcome as Scenario A: a rigorous confirmation that the best available options are those already considered.

Yes. In many medical situations, standard approaches constitute the first line of care but do not represent the full range of available options.

Alternatives may exist in different forms: new generations of pharmacological approaches, non-pharmacological options validated in certain centres, approaches approved in other jurisdictions and accessible through specific routes, or therapeutic innovations carried by low-visibility actors.

It is essential to distinguish scientifically validated alternatives from approaches whose efficacy remains uncertain. A different option is not automatically a better one. We select only options that have an established scientific basis and a recognised regulatory authorisation.

Medical practices evolve at different rates depending on countries, institutions and specialties. An approach developed in an expert centre may take several years to spread, and may never spread to certain regions of the world.

To know whether a different approach exists elsewhere, one must examine the recommendations of the major international learned societies, the practices documented in expert centres, and conduct direct enquiries with the most specialised teams.

This process may reveal strategies that do not yet feature in local practice: a combined approach, a technique validated in a single centre, or an option approved in another jurisdiction. The Global Therapeutic Exploration systematically covers this dimension.

Reducing this risk is one of Bytlian's central concerns. The Therapeutic Intelligence Gap is structural: the production of medical knowledge advances faster than its dissemination. What the treating team does not know, it does not know that it does not know.

Reducing this risk involves a structured, independent process: analysis of recent publications in the relevant sources, exploration of options validated in other jurisdictions, identification of expert centres, field enquiries, and validation by a scientific committee.

We do not guarantee that an additional option exists. We guarantee that if an option exists, it will be sought everywhere it might be found. This guarantee of method is the central value of the service.

An in-depth medical search rests on a clear methodology. One must distinguish scientifically validated information from speculative content, classify the data by level of evidence, and keep a structured record of the avenues already explored.

Defining precise objectives is essential: is one looking for an additional therapeutic option, an expert centre, a validation of the current strategy? These questions strongly direct the process.

Bytlian takes charge of this search in a structured and independent way. The combination of a global documentary infrastructure and direct field investigation makes it possible to go beyond what an individual search can produce, however rigorous.

Taking stock of all available options is a mapping exercise: establishing a global view of the current medical situation and of all the possibilities existing on a worldwide scale.

This process involves examining standard approaches, therapeutic alternatives, recent innovations, the specialised expertise available in different countries, and the specific routes of access to certain options.

Bytlian's deliverable responds precisely to this need: a structured mapping, qualified by level of evidence, with full attribution of sources, designed to be useful to the treating medical team in its exchanges with the patient. It does not constitute a medical opinion. It widens the map available at the moment of decision.

A world specialist in a complex situation is not necessarily the most publicised or the most cited physician in general. It is the professional whose expertise is directly relevant to the patient's precise problem. And these two notions almost never coincide.

Identification requires analysing the scientific literature in the field concerned, the direction of specific research programmes, involvement in expert networks, and the experience accumulated on comparable situations. But it requires, above all, direct enquiry: what peers know about their peers appears in no database.

In certain highly specialised situations, world expertise is concentrated among a small number of teams. Locating them is one of the concrete values of the exploration. And it is one of the tasks that most resists all automation.

A relevant expert centre is not the largest or the best known. It is the one that concentrates real, demonstrable experience of the medical situation concerned: volume of patients treated, publications in that precise field, and recognition by peers within specialised networks.

In some situations, only a few centres concentrate a significant share of the world's expertise. They often collaborate within international networks and are barely visible from within a single health system. Some have no internet presence. Some do not wish to make themselves known.

Bytlian identifies these centres as part of its explorations. The aim is not to build a general ranking but to identify the teams whose expertise is directly applicable to the patient's situation.

Knowledge about uncommon medical situations is often scattered across little-circulated publications, specialised registries, expert networks and reference centres. It is not gathered in a single place, and a large part of it is not public.

A thorough understanding requires cross-referencing several sources: specialised scientific literature, reference-centre data, and direct enquiries with the most involved teams.

This is the process Bytlian conducts as part of its explorations: combining a global documentary infrastructure with direct field investigation, to produce a coherent picture of what exists.

The most active researchers in a field stand out through their recent publications, their direction of research programmes, and their participation in specialised networks. But the most advanced are not always the most visible: some hold back their results, others do not publish, still others belong to no official network.

Identifying these researchers makes it possible not only to understand where the most advanced knowledge is developing, but also to locate the actors who might hold information not yet accessible through documentary routes.

Bytlian carries out this identification as part of its explorations. The most active researchers may be among the direct contacts of the field investigation, in addition to documentary analysis.

Medical innovation is distributed worldwide. For a given situation, the most relevant advances may be found in unexpected countries, with no connection to their size, their wealth or their general reputation in healthcare.

Identifying the countries most advanced on a precise problem requires examining the volume of publications, the presence of recognised expert centres, and participation in international networks. But that is not enough: some institutions develop advanced practices that are the subject of no international publication.

Bytlian covers the entire world in its explorations precisely because the geography of medical innovation does not match the geography of the usual health systems.

When no option seems obvious from within the usual health system, the question is whether this impression reflects the reality of the global medical ecosystem or simply the limits of the visibility available.

Structured exploration starts from this question. It examines the entire global therapeutic landscape: options validated in other jurisdictions, approaches under evaluation, practices developed in low-visibility centres, innovations carried by actors with no dissemination infrastructure.

The result may be a confirmation that the options already considered are indeed the best available. It may also reveal avenues not yet considered. In both cases, the process produces value.

In complex medical situations, experience is often a decisive factor. Some teams have seen hundreds of comparable situations over the years, while others encounter the problem only occasionally.

Identifying these teams resists any purely documentary approach. An experienced team does not necessarily publish. It may belong to no formal network. It may be known only to its immediate circle.

Direct investigation is often the only way to find them. This is why Bytlian regularly combines documentary analysis with field enquiry.

In the vast majority of situations, accessing international expertise does not require physical travel. What is decisive is access to the information produced by that expertise: protocols, practices, guidance, and sometimes a remote consultation.

Bytlian produces a structured deliverable designed to be passed to the treating medical team. The team can integrate it into its exchanges with the patient and, if a highly specific international expertise is identified, organise a remote consultation or collaboration.

Access to world expertise begins with identification: knowing who knows what, where, with what results. It is this mapping that the Global Therapeutic Exploration produces.

An innovation developed in one field may sometimes be of interest for other situations sharing common underlying mechanisms. Conversely, some heavily publicised innovations concern only a very narrow profile.

Determining whether an innovation is relevant requires analysing its mechanism of action, the clinical profiles studied, and the results obtained. This analysis is inseparable from identification.

This is the role of Bytlian's independent scientific committee: to qualify each option identified in light of the patient's clinical profile, and to distinguish genuinely relevant innovations from those that, however interesting, have no concrete application in the situation under study.

Approaches under clinical evaluation are options that have not yet completed the steps required for full validation. They are not the first avenue to explore: Bytlian first seeks fully validated and available options. It is only when these are insufficient or non-existent that approaches under evaluation become relevant.

Moreover, clinical-trial programmes are not uniformly distributed across the world. In many countries they are few or practically absent, which makes access to them structurally complex for members residing in those territories.

When an approach under evaluation is relevant to a given case, Bytlian's scientific committee qualifies its stage of development, assesses the available data, and documents the realistic conditions of access. We also support the patient who wishes to take part, in order to optimise their chances of being recruited.

Exploring the scientific literature on a specific medical situation requires selecting the most reliable, the most recent, and the most directly relevant sources. Not all publications have the same methodological value.

An effective exploration identifies the authors and teams that publish regularly on the situation concerned, the journals in which these publications appear, and the results on which the scientific community agrees.

Bytlian accesses more than 26,000 scientific journals, including a significant proportion of private or institutional sources not accessible through a standard search. The critical analysis of these publications is conducted as part of every exploration.

Complex medical situations are often studied by international networks bringing together researchers, clinicians, laboratories and expert centres. These networks pool knowledge and accelerate scientific progress.

Identifying them makes it possible to locate the teams most involved in a field. Scientific publications, medical congresses, specialised associations and reference centres often serve as entry points.

Bytlian integrates the identification of these networks into its explorations. They also constitute a source of direct investigation: the members of these networks are among the contacts mobilised in the field-enquiry layer.

Every clinical trial rests on precise inclusion and exclusion criteria: type of medical situation, level of progression, options already received, biological characteristics, general condition. These criteria determine who may take part.

Assessing a trial's relevance requires comparing these criteria with the patient's clinical profile, and analysing the study's stage of development, its objectives and the methodological quality of the protocol.

Bytlian's scientific committee conducts this assessment as part of every exploration. The aim is not to identify as many trials as possible, but those whose therapeutic hypotheses and eligibility criteria genuinely match the patient's profile.

In rapidly evolving medical fields, innovative approaches may emerge at a pace that outstrips the dissemination of official recommendations. An option validated in one centre may take years to be integrated into standard practice.

An effective search in these fields requires continuous monitoring of publications, specialised congresses, active clinical trials and the work of the most active teams.

Bytlian offers this dimension within the Medical Family Office: continuous, personalised monitoring, activated proactively so that new options are identified as they emerge, not afterwards.

The more specific a medical situation, the more its exploration requires a high degree of methodological precision. General information sources do not make it possible to identify options suited to very precise clinical profiles.

This precision requires access to the most granular data: clinical-trial results stratified by subgroup, publications on similar biological profiles, the practices of expert centres that have seen comparable situations.

This is the value of combining a documentary infrastructure with direct field investigation. The teams that have seen comparable situations are often the best sources of information on what works.

Specialised medical resources, targeted publications, patient registries, institutional databases, expert-network recommendations, are rarely gathered in a single place. Exploring them requires a suitable methodology and institutional access.

Bytlian accesses more than 40 specialised databases, including a significant proportion of private sources, inaccessible through a standard internet search. Private or paywalled sources account for roughly 60% of clinically relevant information.

The aim is to build a coherent picture from sometimes fragmented data, and to transform it into a structured, qualified report useful to the treating medical team.

Recognised experts on a rare medical problem can be identified through their publications, the clinical trials they lead, their presence in medical recommendations, and their involvement in specialised networks. In some fields, only a few dozen experts concentrate a significant share of the world's experience.

The aim is not to identify the best-known professionals in general, but those whose expertise is directly relevant to the problem under study.

Bytlian carries out this identification as part of its explorations, combining documentary analysis with direct enquiry within specialised networks.

Medical practices vary between countries for many reasons: organisation of health systems, access to therapeutic options, regulatory frameworks, clinical traditions, and the pace of adoption of innovations.

Comparing these practices makes it possible to identify approaches validated elsewhere that are not yet integrated into local practice. This comparison is not aimed at ranking health systems but at understanding the diversity of available options.

The Independent Global Therapeutic Exploration explicitly covers this dimension. Its geographic scope is worldwide because medical innovation is distributed worldwide.

The existence of active research on a medical situation is a positive signal: it reflects the scientific interest in that problem and the likelihood that new options will emerge.

The sources to consult are clinical-trial registries, recent scientific publications, specialised congresses, expert centres and international research networks.

Even when the results of this research are not immediately applicable, following its evolution makes it possible to understand the future direction of the field. Bytlian integrates this prospective dimension into its explorations and into the continuous monitoring offered to members.

Emerging therapeutic opportunities are approaches that are beginning to attract the attention of the scientific community without yet being fully integrated into routine medical practice. They may represent important prospects, particularly in situations where validated options are limited.

Identifying them requires monitoring scientific publications, clinical trials, and the work of the most active research teams. An emerging innovation is not a validated solution: its potential must be assessed in light of the available data and its stage of development.

This is the role of Bytlian's independent scientific committee: to distinguish promising opportunities from still-speculative hypotheses, and to qualify each option according to its level of clinical maturity.

The Medical Family Office is Bytlian's positioning and the promise it carries for its members. The concept draws on the financial family office: an independent support structure, founded on continuity and relationship.

A financial family office does not manage assets directly. It selects, coordinates and oversees the best specialists on behalf of the family, anticipating risks before they become crises.

The Medical Family Office applies the same logic to vital capital: the health and functional capacity of the people who matter. It does not replace physicians. It ensures that physicians have the best global information at the moment of each important decision.

A financial family office is set up well before any wealth crisis. It monitors, anticipates, and mobilises resources at the right moment. Few wealthy families make important financial decisions without an infrastructure of analysis and independence.

The same logic applies to vital capital. A complex medical situation can arise at any moment. The decisions that follow may be irreversible. Making them with incomplete information, for lack of an exploration infrastructure, is a risk that can be reduced.

The Medical Family Office is precisely that infrastructure: set up before any crisis, operational within the hour when a situation requires it, independent of any commercial or institutional interest.

Shadow Care denotes an informal, long-standing practice, until now reserved for a very small number of families: in the face of a complex medical situation, mobilising a team of researchers, scientific advisers and independent specialists to ensure that no relevant option in the world remains unexplored.

This approach operates in the shadows, in parallel with conventional care, without replacing it. What sets it apart is not access to secret options. It is access to information: structured, global, exhaustive, delivered in time to change the course of a decision.

An effective practice, Shadow Care suffers from three flaws that the urgency of a medical situation makes particularly critical: a price out of reach for most people, a deployment time measured in weeks or even months when every day counts, and no real guarantee of independence for experts recruited in haste, sometimes too close to the solutions or institutions they are meant to evaluate. Bytlian is the formalisation and scaling of this approach, made accessible notably on subscription.

The Medical Family Office is the name given to this permanent infrastructure of independent therapeutic intelligence.

The Therapeutic Intelligence Gap is Bytlian's founding concept. It denotes the gap between the therapeutic options that exist in the world at a given moment, and those that actually reach the patient at the moment they need them.

This gap is fed by many structural forces: dissemination delays, commercial barriers, institutional silos, human limits, academic rivalries, regulatory complexity. It does not result from a failure of the health system. It is the mechanical consequence of a world in which the production of medical knowledge structurally outpaces the infrastructure designed to spread it.

The Therapeutic Intelligence Gap is widening. The curve of knowledge production is steeper than the curve of dissemination. Bytlian is the response to this growing structural problem.

The Invisible Gap is the French name for the Therapeutic Intelligence Gap. It denotes, for a given patient at a given moment, the difference between what exists in the world and what is visible to them and their medical team.

It is invisible by definition: neither the patient nor the physician knows what is missing. One cannot point to an absence. But one can measure its consequences: the protocol that did not spread, the option available elsewhere that was not identified, the specialist who was not found.

It is precisely because the gap is invisible that a dedicated infrastructure is needed to close it. Bytlian has built that infrastructure over ten years of scouting global innovations.

A medical concierge facilitates access to an already-identified care offering: rapid appointments, referral to network specialists, logistical coordination. Its value lies in smoothing access to known options.

The Medical Family Office acts upstream of a different question: what are the best options available in the world for this precise situation? It identifies what should be considered before deciding whom to turn to.

One optimises the path to a known destination. The other ensures the right destination has been identified. The two are complementary.

A second medical opinion consists of submitting a case to another physician, who forms their own clinical reading of it. The informational perimeter stays the same: another view of the same data.

Bytlian's Independent Global Therapeutic Exploration widens the informational perimeter itself. It identifies options the treating team has not yet examined, not because it lacks competence, but because they lie in sources that no medical team can monitor on its own.

The second opinion deepens the analysis of a known landscape. Bytlian ensures that landscape is complete. The two approaches are complementary, not substitutable.

Bytlian uses assisted documentary-exploration tools, but the difference from a general-purpose medical AI tool is structural, not one of degree.

General-purpose AIs access the public internet, which represents a fraction of clinically relevant information. Bytlian accesses the private, institutional and unpublished sources these tools do not see. What a tool does not see, it cannot point to, and it does not know that it does not see it.

Second, human validation. Every Bytlian deliverable is validated by an independent scientific committee that qualifies the levels of evidence and assumes intellectual responsibility for the document. Third, direct investigation: Bytlian conducts enquiries with specialists and researchers to identify what no documentary corpus yet contains.

Bytlian's Medical Family Office is for individuals and families who want the assurance of being perfectly informed if they, or a loved one, face a complex medical situation.

The maximum value of the service is anticipatory: it is subscribed before any illness. Members who activate the service in an emergency benefit from a start within the hour.

Bytlian is for people who apply to their health, and that of their loved ones, the same rigour as to their professional or wealth decisions.

The principle of non-substitution is the first and most fundamental of Bytlian's principles. It means that Bytlian does not prescribe, does not diagnose, and does not replace any physician.

The Bytlian deliverable is designed for the treating medical team, not for the patient acting alone. It widens the map available at the moment of the clinical decision. But the decision itself remains the exclusive prerogative of the physician, who alone knows the patient as a whole.

This principle is not a legal precaution. It is a design choice: the service is more useful when it knows where it stops. The treating physician knows the patient. We know the global landscape. The combination is the goal.

Bytlian's independence is structural, not declarative. Bytlian has no commercial or financial relationship with any solution, institution or specialist it identifies.

Members pay for an exploration. No part of the fee is contingent on the nature of the results. No provider of an identified option compensates Bytlian in any form whatsoever.

Scientific-committee members disclose their conflicts of interest before any participation. In the event of a conflict, they are replaced. The committee's composition is documented in every deliverable.

The scientific committee is the guarantor of the quality and responsibility of every Bytlian deliverable. It is constituted ad hoc for each case, according to the patient's clinical profile and the nature of the question posed.

Depending on the case, it includes specialised clinicians, regulatory experts, academic researchers, and specialists in the scientific literature of the field concerned. Each member discloses their conflicts of interest. In the event of a conflict, they are replaced.

The committee directs the exploration, validates the results, prioritises the options identified, and assumes full intellectual responsibility for the document. No deliverable passes this stage without human validation.

The Constellation is the name Bytlian gives to the body of documentary sources we have identified and the proprietary resources we maintain continuously. It bears this name because it reflects the reality of global medical innovation: a multitude of points of varying brightness, scattered through space, in highly varied languages, formats and access systems, of which no actor can claim a complete view without a dedicated infrastructure and organisation.

Its strength lies not in the possession of data, but in the ability to access it at the moment a case requires it. This ecosystem, which comprises our proprietary resources and the connections that make it possible to reach sources scattered across the world at the moment a case requires, cannot be improvised and cannot be replicated.

The Independent Global Therapeutic Exploration (IGTE) is a discipline created by Bytlian to address the Therapeutic Intelligence Gap.

It is defined as the systematic, global and independent mapping of all the therapeutic options relevant to a given patient's clinical profile, conducted on the basis of public and private sources, complemented by direct investigation, validated by an independent scientific committee, and delivered in a format designed to be useful to the treating medical team.

It differs from a second medical opinion by its global scope and its access to private sources. It differs from a medical concierge by its ability to identify options unknown to the treating team. It differs from a generative-AI tool by its human validation and its access to multiple, heterogeneous sources inaccessible to general-purpose models. More information at bytlian.com

Care for One is Bytlian's permanent solidarity commitment. For every exploration carried out under a paid subscription, Bytlian undertakes to make the results benefit another patient with no financial resources.

Beneficiaries are selected by a dedicated committee, on the basis of clinical urgency, the complexity of the situation, and the absence of resources. The exploration delivered is identical in methodology, rigour and quality to any other Bytlian exploration. There is no two-tier service.

The anonymity of both the beneficiary and their benefactor is fully guaranteed.

The funding of this initiative is independent, does not rely on fundraising, and is not subject to donation cycles. This commitment is structural, unconditional and natively embedded in the company's business model.

Bytlian's methodology for exploring and evaluating global therapeutic options was developed over ten years in partnership with CentraleSupélec / Université Paris-Saclay, ranked first worldwide in mathematics in the Shanghai Ranking.

This collaboration made it possible to develop the methods and tools for exploring complex documentary corpora, qualifying levels of evidence, and structuring the deliverables.

This academic partnership constitutes the methodological foundation of the service. It distinguishes Bytlian from an empirical approach and guarantees a reproducible rigour in every exploration.

The value of a Medical Family Office is greatest when it is set up before any crisis. Like a financial family office, it monitors, anticipates, and stands ready to mobilise its resources at the right moment.

A member who activates Bytlian in an emergency benefits from a start within the hour. But a member who subscribed in anticipation additionally benefits from a knowledge of their profile, an established relationship, and continuous monitoring of relevant developments in the fields that concern them.

Modern medicine advances faster than its dissemination. An option that did not exist a year ago may appear today. Continuous, personalised monitoring is an effective way not to miss that window.

Confidentiality is a fundamental operational principle of Bytlian. Patient data is anonymised before any exploration. No third party, including scientific-committee members or database providers, receives information that could identify the patient.

All deliverables are produced in writing. No oral recommendations are issued. The data handled in the course of an exploration is not retained beyond the case's operational needs.

Confidentiality is also a condition of independence: a service that shares its members' data with commercial providers cannot claim structural independence.

Finally, the technical infrastructure is built on AWS (Amazon Web Services), certified ISO 27001, SOC 2 Type II and HIPAA. Data is hosted and processed in compliance with the major regulations in force: the European GDPR, the Swiss nFADP, the Japanese APPI and the US HIPAA.

The main medical challenge of the coming decades will not be solely the production of new knowledge. It will be its accessibility. The curve of medical-knowledge production is steeper than the curve of dissemination, and this gap will structurally widen.

Bytlian's vision is to become the global reference for Independent Global Therapeutic Exploration: the permanent infrastructure that makes global therapeutic information accessible, qualified and actionable for everyone, not only for families with the resources to search for it themselves.

Bytlian is not a one-off solution to an existing problem. It is a permanent infrastructure for a structurally growing one.

Access to a structured therapeutic exploration has historically been reserved for families with the resources to assemble an ad hoc research team. Shadow Care is a real, long-standing and unevenly distributed practice.

Bytlian makes accessible on subscription a methodology that previously required considerable resources. It also offers the Care for One programme, which funds a complete exploration for a patient with no resources for every paid exploration carried out. Unlike Shadow Care, our explorations can be deployed immediately, without the three structural limits inherent to Shadow Care described in Q63: prohibitive cost, deployment time, and the genuine independence of the experts consulted.

The aim is not to guarantee immediate universal access, but to structurally reduce the gap between those for whom a global exploration is possible and those for whom it was not.

Bytlian rests on a multi-layered architecture operating in a structured sequence. The first layer is documentary: access to all proprietary and external databases, including private and institutional sources unreachable by standard routes. The second is a direct-investigation layer: enquiries with specialists, researchers and other actors in the medical ecosystem. The third is validation by the independent scientific committee, constituted ad hoc for each case.

These three layers are not rigidly sequential. Direct investigation may steer the documentary research. The committee may request additional investigations. The complexity of some cases requires back-and-forth that nothing mechanises.

It is this operational complexity that distinguishes Bytlian from a database-querying service or from generative AI. Nothing passes without human validation.

Bytlian conducts a systematic, global and independent exploration of the therapeutic options relevant to a given clinical profile. It combines access to public and private documentary sources, direct investigation with specialists and researchers, and validation by an independent scientific committee.

It produces a structured document, the "Personal Medical Intelligence Brief", designed for the treating medical team: a qualified mapping of the options identified, with levels of evidence, regulatory status in the relevant jurisdictions, and expert contacts.

Bytlian does not prescribe. It does not diagnose. It does not treat. It widens the map available at the moment of the clinical decision. This document does not constitute a medical act.

No. The principle of non-substitution is absolute and fundamental in Bytlian's architecture.

Physicians are the only professionals authorised to diagnose, prescribe and make therapeutic decisions. Bytlian does not intervene in that space. Its synthesis report, the "Personal Medical Intelligence Brief", is designed for the medical team, not for the patient acting alone.

In more than 200 interviews conducted with general practitioners and specialists, half spontaneously asked for a version of the service oriented towards their own practice. Physicians do not resist additional information. They know that the complete landscape is not accessible through standard routes. Bytlian is designed to be their ally.

Explorations are conducted by a combination of technological infrastructure and human expertise. The documentary layer is managed by specialised exploration tools. The field-investigation layer is conducted by professionals with strong experience in scouting global innovations.

Final validation is provided by the independent scientific committee, constituted ad hoc for each case. This committee includes clinicians, regulatory experts and researchers whose profile matches the clinical question posed.

Each committee member discloses their conflicts of interest before any participation. In the event of a conflict, they are replaced. The committee's composition is documented in the synthesis report.

Identifying options rests on the simultaneous exploration of several universes of information: public and private scientific literature, institutional databases, recent medical recommendations, and direct enquiries with specialists and researchers.

Each source brings a different perspective. Some reveal validated options that are little disseminated. Others identify emerging approaches. Still others, accessible only through field investigation, make it possible to find what no documentary corpus yet contains.

Identification is always followed by qualification: the scientific committee assesses the relevance of each option identified in light of the patient's clinical profile.

Bytlian is relevant to any medical situation for which the global landscape of therapeutic options has not yet been systematically mapped.

This includes complex or rare situations, but also common ones: a complex orthopaedic situation, an unresolved autoimmune condition, a chronic situation for which standard approaches do not yield the expected result, or simply the wish to ensure that care matches the global state of the art.

Bytlian is not a last-resort service. It is an exploration service, relevant at any stage of a medical situation, from the moment of diagnosis for members who subscribed in anticipation.

A Bytlian exploration begins with the receipt and analysis of the available medical case file. This step makes it possible to understand the clinical profile, the options already considered or applied, and the precise question the exploration must answer.

An in-depth investigation phase is then conducted, combining documentary exploration with field enquiry among specialists and researchers. The independent scientific committee then validates the results, redirects the exploration if necessary, prioritises the options and produces the final deliverable.

This document is handed to the medical team in charge of the patient, which may decide to share it with them. The exploration can be launched within the hour following receipt of a complete case file.

The medical team receives a structured document, written in a clinical register, with full attribution of sources. It presents all the therapeutic options identified, qualified by level of evidence and regulatory status, with their geographic availability and the contacts of the reference specialists or centres.

The document includes a complete methodological disclosure: sources consulted, full sources when they can be shared, databases queried, database extractions, scientific-committee composition, interview reports, and so on. A complete report runs between 100 and 300 pages depending on the situation studied.

All therapeutic decisions remain the exclusive prerogative of physicians. The deliverable is designed to enrich their thinking, not to replace it.

Bytlian favours the sources with the highest level of scientific reliability: publications in peer-reviewed journals, recommendations from recognised learned societies, regulatory submissions, institutional data, and also industrial, economic or legal data.

Not all available information has the same level of reliability. Particular attention is paid to the methodological robustness of studies, their level of evidence, and their clinical relevance in the context of the case studied.

This rigorous selection is a condition of the deliverable's credibility. A document handed to a professional medical team must rest on sources it can itself verify and assess.

Analysing the results is not about accumulating information. It aims to build a coherent, qualified mapping of the options relevant to a precise clinical profile.

Each option identified is placed back in its scientific and regulatory environment. Its level of evidence, its limits, its stage of clinical development, and its potential relevance to the patient's profile are assessed.

This analysis is conducted by the independent scientific committee, which distinguishes immediately applicable options from those that require additional investigation, and from those of prospective interest.

Bytlian uses technological tools, including assisted-exploration tools, as a documentary-exploration layer. These tools query our databases and external sources, identify candidate options, and structure the results. They are means, not the service.

The difference from a general-purpose tool is structural: Bytlian accesses sources these tools do not see, and systematically validates their results through an independent scientific committee. A tool cannot point to what it does not see, and does not know that it does not see it.

The validation of everything the technological layer produces is conducted by the scientific committee. The tool explores and structures. The committee validates, directs and assumes responsibility. No deliverable passes validation automatically.

Bytlian's independence rests on three structural pillars. First pillar: the absence of any commercial or financial link with the options identified. No provider, no centre, no specialist compensates Bytlian for being identified in a deliverable.

Second pillar: the management of conflicts of interest within the scientific committee. Each member discloses their conflicts before any participation. In the event of a conflict, they are replaced. The committee's composition is documented in the deliverable.

Third pillar: the global scope of the exploration. By searching across the entire world through multiple, heterogeneous sources, we mechanically reduce the risk that a geographic, institutional, regulatory, linguistic or commercial bias narrows the field of options identified.

No. Bytlian has no network of partners towards which it steers its members. The exploration always starts from the patient's clinical profile to identify the most relevant options, independently of any predefined institution or network.

In some cases, the exploration identifies highly relevant centres or specialists. In others, several options are presented with their differences. In every case, it is the treating medical team that decides.

The absence of a partner network is a condition of Bytlian's structural independence. A service that steers towards its partners, as is the case with certain services particularly in the US, is not independent and may therefore lose objectivity and relevance for the patient.

The general reputation of a healthcare institution is a useful signal, but it says almost nothing about its relevance to a precise medical situation. A centre world-renowned in many fields may not be the right contact for a particular problem. And conversely, some of the most advanced centres on a given subject are barely visible to the general public, little present in general rankings, and sometimes unknown outside the narrow circle of specialists working on that subject.

Several mechanisms explain this invisibility. A centre may concentrate exceptional expertise on a specific situation without having the resources or the interest to communicate it widely. A team may have developed an advanced practice without ever formalising it in a publication, for lack of interest or to protect it through secrecy. Remarkable results may remain confined to one institution for lack of a network, as a commercial strategy, or simply because no one has yet connected what that team can do with what a given patient needs.

This is one of the reasons why the Independent Global Therapeutic Exploration cannot be reduced to consulting rankings or databases.

An expert centre is distinguished by its level of expertise on a precise problem, not always by its reputation.

Bytlian can identify some of these centres as part of every exploration, with no commercial bias. The sole criterion is relevance to the clinical situation studied.

Not all innovations have the same level of clinical maturity. Bytlian systematically distinguishes options with full regulatory authorisation, options under advanced clinical evaluation, approaches under specific access, and innovations still at early stages.

This qualification is conducted by the independent scientific committee. It rests on the analysis of the mechanism of action, the published results, the methodological quality of the studies, and the reproducibility of the observations.

Bytlian identifies only options that have an established scientific basis and a recognised regulatory authorisation. Approaches with no scientific basis or no regulatory sanction are categorically excluded.

No. Bytlian performs no medical diagnosis. Diagnosis is exclusively the province of healthcare professionals authorised to examine patients, interpret medical tests and make the corresponding clinical decisions.

Bytlian always starts from a diagnosis already established by the treating medical team. Our role is to explore the therapeutic options available in the world for that diagnosis, not to establish or challenge it.

This distinction is fundamental in the service's architecture and in its legal and regulatory positioning.

No. Bytlian prescribes no treatment. Medical prescription is an act reserved for authorised healthcare professionals.

The Bytlian deliverable presents therapeutic options that have been identified and qualified. It does not indicate which treatment should be used. It makes no direct therapeutic recommendation and does not constitute a medical opinion.

All therapeutic decisions remain exclusively the responsibility of the physicians in charge of the patient.

Because modern medicine and research produce knowledge faster than it spreads. Because a substantial part of clinically relevant data is inaccessible through a standard search. Because medical innovation develops in geographic areas, companies, institutions and departments that are sometimes beyond the reach of the channels through which medical information usually circulates.

Bytlian was designed to address this problem structurally: to build a permanent infrastructure of independent global therapeutic exploration, accessible primarily on subscription, which ensures that if a relevant option exists somewhere in the world, it will be identified.

The aim is not to call into question the care planned or received. It is to ensure that medical decisions are made with the most complete map possible of the global therapeutic landscape.

There is no single moment to turn to Bytlian. The service's value is expressed at different stages.

In anticipation, before any complex medical situation: this is the maximum value of the membership, like a financial family office set up before any crisis. Continuous monitoring makes it possible to be informed of new options as they emerge.

At the moment of a diagnosis: to ensure that all the options available in the world have been identified before any important therapeutic decision.

When options seem limited: to verify methodically that the global landscape has been explored, confirm or refute that impression, and identify any avenues not yet considered.

Bytlian's main objective is to reduce the Therapeutic Intelligence Gap: the gap between the therapeutic options that exist in the world and those that actually reach the patient at the moment they need them.

To achieve this, Bytlian has built a permanent infrastructure of Independent Global Therapeutic Exploration: a methodology developed over ten years in partnership with CentraleSupélec / Université Paris-Saclay, access to numerous public and private documentary sources, a direct field-investigation layer, and an independent scientific committee that validates every deliverable.

Bytlian does not promise to find an answer. It promises that if an answer exists, somewhere in the world, it will be sought. To learn more: bytlian.com

This document does not constitute a medical act. Bytlian does not diagnose, does not prescribe and does not treat.

bytlian.com | June 2026